SOBRsafe Inc., a technology company focused on innovative alcohol detection solutions, has made significant leadership additions to support its continued growth and technological advancement. The company has appointed Kris Pederson to its Board of Directors and named Dr. Benjamin Sanchez as a Scientific Advisor, bringing extensive expertise in corporate governance, digital innovation, and biomedical engineering.
Pederson, a veteran corporate director with notable leadership experience at prominent firms including EY, IBM, and PwC, will join the board effective May 1, 2025. She will also chair the Nominating and Corporate Governance Committee, leveraging her extensive background in strategic leadership and corporate management to guide SOBRsafe's governance strategies.
The appointment of Dr. Benjamin Sanchez as Scientific Advisor in February represents another strategic move to strengthen the company's research and development capabilities. His expertise is expected to support federal funding initiatives and enhance clinical research partnerships, critical components for advancing SOBRsafe's technology platform.
SOBRsafe's technology addresses a significant public health challenge, as alcohol misuse remains the fourth leading cause of preventable death in the United States and seventh worldwide. The company's innovative transdermal detection technology offers a non-invasive, instantaneous method of alcohol detection through skin contact, presenting a novel approach to monitoring and prevention.
The company's technology platform includes two primary products: SOBRcheck for point-of-care screening and SOBRsure for continuous monitoring. These solutions aim to provide comprehensive alcohol detection capabilities across behavioral health, judicial, and consumer markets, with potential applications in workplace safety, rehabilitation programs, and personal health management.
By integrating Pederson's governance expertise and Sanchez's scientific knowledge, SOBRsafe is positioning itself to expand its technological capabilities and market reach. The strategic appointments underscore the company's commitment to innovation, scientific rigor, and addressing critical public health challenges through advanced detection technologies.
